An intragenic deletion of the factor IX gene in a family with hemophilia B.

S H Chen; S Yoshitake; P F Chance; G L Bray; A R Thompson; C R Scott; K Kurachi

doi:10.1172/JCI112222

Find articles by Chen, S. in: PubMed | Google Scholar

Find articles by Yoshitake, S. in: PubMed | Google Scholar

Find articles by Chance, P. in: PubMed | Google Scholar

Find articles by Bray, G. in: PubMed | Google Scholar

Find articles by Thompson, A. in: PubMed | Google Scholar

Find articles by Scott, C. in: PubMed | Google Scholar

Find articles by Kurachi, K. in: PubMed | Google Scholar

Published in Volume 76, Issue 6 on December 1, 1985
J Clin Invest. 1985;76(6):2161–2164. https://doi.org/10.1172/JCI112222.
© 1985 The American Society for Clinical Investigation

Published December 1, 1985 - Version history

A family of seven patients severely afflicted with hemophilia B has been studied for their factor IX genes through the use of factor IX cDNA and genomic DNA probes. The patients had detectable (less than 10% of normal) factor IX antigen in urine and no detectable inhibitors in sera to factor IX protein. Based on the DNA hybridization analysis, these patients showed a partial intragenic deletion in their factor IX gene. The deletion included two exons (exons V and VI) coding for the amino acid sequence from number 85 to 195 of the factor IX protein. The deleted portion of the gene contained the entire factor IX activation peptide. The length of the deletion was estimated to be 10 +/- 0.3 kilobase pairs. This specific gene has been named FIXSeattle. In this family both the deletion and a Taq 1 restriction fragment length polymorphism can be used as a useful marker for accurate detection of female carriers of the deficient factor IX gene.

Images.

Click on an image below to see the page. View PDF of the complete article